Small study explores real-world switch to riociguat for tough PAH cases

NCT ID NCT07374302

Not yet recruiting Knowledge-focused Sponsor: Caio Júlio César dos Santos Fernandes Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will review medical records of 15 adults with pulmonary arterial hypertension (PAH) who switched from one medication (a PDE5 inhibitor) to riociguat while already on triple therapy. The goal is to see if this switch improves exercise ability, symptoms, and blood markers at 6 months. Because it is a retrospective chart review, no new treatments are given, and the results will only describe what happened in routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: riociguat
What this could lead to: If results are positive, this could suggest that switching to riociguat is a useful option for PAH patients not doing well on standard triple therapy.
What could go wrong: This is a very small (15 people), single-center, retrospective study, so results may not apply widely. It only observes routine care, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.